Latest Ratios: P/E Ratio -5.0x · EV/EBITDA N/A · ROE -43.1%. (2004–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $251M | $759M | $474M | $523M | $794M | $1.3B | $265M | $155M | $122M | $169M | $128M |
| Enterprise Value | $149M | $656M | $342M | $372M | $645M | $1.1B | $236M | $132M | $99M | $142M | $118M |
| P/E Ratio → | -5.02 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.44 | 8.00 | 3.94 | 3.68 | 5.57 | 8.31 | 9.72 | 7.62 | 5.95 | 6.97 | 20.23 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -43.1% | -43.1% | -32.8% | -33.4% | -32.7% | -42.6% | -110.6% | -129.0% | -78.0% | -88.1% | -154.2% |
| ROA | -38.7% | -38.7% | -29.7% | -30.9% | -30.5% | -38.7% | -87.8% | -105.8% | -66.9% | -72.1% | -118.0% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROCE | -47.8% | -47.8% | -40.3% | -39.2% | -34.8% | -47.2% | — | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.08 | -1.10 | -1.06 | -1.05 | -1.01 | -1.07 | -1.09 | -1.12 | -1.13 | -1.46 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -48.28 | — | — | — | — | — | — | — |
Net cash position: cash ($103M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.60 | 11.60 | 8.86 | 12.32 | 14.95 | 14.97 | 4.73 | 5.03 | 6.26 | 7.75 | 2.96 |
| Quick Ratio | 11.60 | 11.60 | 8.86 | 12.32 | 14.95 | 14.97 | 4.73 | 5.55 | 6.26 | 7.75 | 2.96 |
| Cash Ratio | 11.47 | 11.47 | 8.64 | 12.05 | 14.60 | 14.09 | 4.00 | 4.40 | 5.90 | 7.66 | 2.88 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $85M | $83M | $80M | $77M | $70M | $58M | $49M | $45M | $41M | $35M |
Binary Clinical Trial Outcomes
According to recent market data, AVXL trades at a price-to-book ratio of 2.36, a valuation that appears to reflect speculative anticipation of clinical success rather than any underlying fundamental support from earnings or revenue, which remain absent in the company's current pre-commercial stage of development.
The lack of meaningful P/E or P/S multiples renders traditional valuation metrics largely inapplicable, forcing investors to rely on the implied probability of technical and regulatory success. This valuation suggests that the market is pricing in a high-probability outcome for its lead pipeline assets, which may be disconnected from the inherent risks of regulatory rejection or trial delays.
Based on reported financial statements, the company maintains a current ratio of 20.87 as of 2026Q1, a figure that appears deceptively strong but actually reflects a lack of significant short-term liabilities rather than a robust, self-sustaining liquidity position capable of funding long-term R&D requirements.
While the high ratio suggests an ability to cover immediate obligations, it masks the reality that the company is consuming its cash reserves to fund clinical trials. Investors should monitor the cash runway closely, as the absence of revenue means that liquidity is entirely dependent on the company's ability to access capital markets through dilutive equity offerings.
As indicated by comparative analysis, AVXL's valuation profile differs significantly from commercial-stage peers like ACAD, which maintains positive margins and established revenue, whereas AVXL remains a pre-revenue entity whose market capitalization is driven almost exclusively by the binary potential of its CNS pipeline.
The gap between AVXL and its peers is structural, as the company lacks the commercial infrastructure and product sales that provide a floor for valuation in more mature biotech firms. This suggests that AVXL's stock price is likely to exhibit higher volatility and sensitivity to clinical trial updates compared to peers with diversified revenue streams.
Financial analysts frequently misapply traditional profitability ratios like net margin to AVXL, which obscures the company's true economic state, as these metrics are inherently negative for a pre-revenue firm and fail to capture the value of the underlying intellectual property or the potential of the pipeline.
Using net margin to evaluate a clinical-stage biotech firm is misleading because it treats R&D investment as a pure loss rather than a capital expenditure aimed at future value creation. A more appropriate approach would involve adjusting for the probability of success and focusing on the cash burn rate relative to the time required to reach the next major regulatory milestone.
Includes 30+ ratios · 22 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AVXL stock.
Anavex Life Sciences Corp.'s current P/E ratio is -5.0x. This places it at the 50th percentile of its historical range.
Anavex Life Sciences Corp.'s return on equity (ROE) is -43.1%. The historical average is -82.2%.
Based on historical data, Anavex Life Sciences Corp. is trading at a P/E of -5.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.